Literature DB >> 10553062

Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence.

A Holz1, A Bot, B Coon, T Wolfe, M J Grusby, M G von Herrath.   

Abstract

The role of the STAT4 signaling pathway in autoimmune diabetes was investigated using the rat insulin promoter lymphocytic choriomeningitis virus model of virally induced autoimmune diabetes. Abrogation of STAT4 signaling significantly reduced the development of CD4+-T cell-dependent but not CD4+-T cell-independent diabetes, illustrating the fine-tuned kinetics involved in the pathogenesis of autoimmunity. However, the absence of STAT4 did not prevent the generation of autoreactive Th1/Tc1 T cell responses, as well as protective antiviral immunity. Protection from insulin-dependent diabetes mellitus was associated with decreased numbers of autoreactive CTL precursors in the pancreas and the spleen and a general as well as Ag-specific reduction of IFN-gamma secretion by T lymphocytes. A shift from Th1 to Th2 T cell immunity was not observed. Hence, our results implicate both CTL and cytokines in beta cell destruction. Selective inhibition of the STAT4 signal transduction pathway might constitute a novel and attractive approach to prevent clinical insulin-dependent diabetes mellitus in prediabetic individuals at risk.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553062

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; C Benou; A D Salama; M J Grusby; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  STAT4 polymorphisms and diabetes risk: a meta-analysis with 18931 patients and 23833 controls.

Authors:  Jian Yi; Xin Fang; Youyun Wan; Juan Wei; Jianjun Huang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  STAT4 genetic polymorphisms association with spontaneous clearance of hepatitis B virus infection.

Authors:  Yanjun Lu; Yaowu Zhu; Jing Peng; Xiong Wang; Feng Wang; Ziyong Sun
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

4.  Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes.

Authors:  A Holz; K Brett; M B Oldstone
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 5.  STAT4: a critical regulator of inflammation in vivo.

Authors:  Mark H Kaplan
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  STAT4 regulates antiviral gamma interferon responses and recurrent disease during herpes simplex virus 2 infection.

Authors:  Alexandra Svensson; Petra Tunbäck; Inger Nordström; Andrey Shestakov; Leonid Padyukov; Kristina Eriksson
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

7.  Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses.

Authors:  Timothy Hoey; Shangming Zhang; Nathan Schmidt; Qing Yu; Shyam Ramchandani; Xiang Xu; Lisa K Naeger; Ya-Lin Sun; Mark H Kaplan
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

8.  Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice.

Authors:  Patricia A Gonnella; Pedro J Del Nido; Francis X McGowan
Journal:  J Clin Immunol       Date:  2009-04-08       Impact factor: 8.317

9.  Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity.

Authors:  Amanda K Huber; Eric M Jacobson; Krystian Jazdzewski; Erlinda S Concepcion; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

10.  Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Mol Vis       Date:  2010-01-26       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.